Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | RET | P07949 | 4/20 | 0.34 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 3/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24176216 | 0.92 | USP30 (0.37) | USP30GPR119RETWNT1GSK3B | |
| SCHEMBL24166214 | 0.89 | USP30 (0.39) | USP30GPR119RETWNT1GSK3B | |
| SCHEMBL26326435 | 0.87 | PARP1 (0.36) | USP30GPR119KLKB1PIK3CD | |
| SCHEMBL24175710 | 0.81 | USP30 (0.39) | USP30GPR119RETWNT1GSK3B | |
| SCHEMBL24176212 | 0.80 | PARP1 (0.35) | GPR119 | |
| SCHEMBL26326433 | 0.72 | NR1D1 (0.34) | GPR119KLKB1PIK3CD | |
| SCHEMBL30586616 | 0.72 | NR1D1 (0.34) | GPR119KLKB1PIK3CD | |
| SCHEMBL24166181 | 0.72 | USP30 (0.33) | USP30GPR119RETIRAK1MET | |
| SCHEMBL26326387 | 0.71 | NPC1 (0.33) | PIK3CD | |
| SCHEMBL30586615 | 0.70 | JAK2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | USP30 2350/4885GPR119 3466/4885RET 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.